Back
Zoomlion Heavy Industry Science and Technology 10K Form
Buy
60
ZLIOY
Zoomlion Heavy Industry Science and Technology
Last Price:
6.65
Seasonality Move:
14.83%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ZLIOY News And Ratings
See the #1 stock for the next 7 days that we like better than ZLIOY
ZLIOY Financial Statistics
Sales & Book Value
| Annual Sales: | $6.66B |
|---|---|
| Cash Flow: | $-248M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $9.39 |
| Price / Book: | 0.71 |
Profitability
| EPS (TTM): | 0.62700 |
|---|---|
| Net Income (TTM): | $528.06M |
| Gross Margin: | $1.83B |
| Return on Equity: | 6.4% |
| Return on Assets: | 2.86% |
Zoomlion Heavy Industry Science and Technology Earnings Forecast
Key Zoomlion Heavy Industry Science and Technology Financial Ratios
- The Gross Profit Margin over the past 27 years for ZLIOY is 27.54%.
- The Selling, General & Administrative Expenses for ZLIOY have been equal to 5.30% of Gross Profit Margin.
- The Research & Development expenses have been 7.31% of Revenue.
- The Interest Expense is 19.70% of Operating Income.
- The Net Earning history of ZLIOY is 7.45% of Total Revenues.
- Per Share Earnings over the last 24 years have been positive in 14 years.
Zoomlion Heavy Industry Science and Technology Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Machinery |
| Sector: | Industrials |
| Current Symbol: | ZLIOY |
| Website: | en.zoomlion.com |
Debt
| Debt-to-Equity Ratio: | 0.45 |
|---|---|
| Current Ratio: | 1.62 |
| Quick Ratio: | 0.93 |
Price-to-Earnings
| Trailing P/E Ratio: | 11.2 |
|---|---|
| Forward P/E Ratio: | 0 |
ZLIOY Technical Analysis vs Fundamental Analysis
Buy
60
Zoomlion Heavy Industry Science and Technology (ZLIOY)
is a Buy
Is Zoomlion Heavy Industry Science and Technology a Buy or a Sell?
-
Zoomlion Heavy Industry Science and Technology stock is rated a Buy
The current Zoomlion Heavy Industry Science and Technology [ZLIOY] share price is $6.65. The Score for ZLIOY is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.